MAPK8 and hepatocellular carcinoma: It is thus possible that LicA may be used as an anti-metastatic agent for the treatment of HCC, as it induces a downregulation of MKK4 and JNK activation, as well as inhibits the expression of uPA, which leads to the inhibition of cell migration and invasion.